IDEX (IEX) Q2 Revenue Jumps 7%

Key Points

• Non-GAAP earnings per share of $2.07 exceeded analyst estimates of $1.995439; GAAP revenue also surpassed forecasts, setting a record at $865 million.

• Operational highlights include robust free cash flow, segment growth led by HST, and continued investment in acquisitions, such as Micro-LAM.

• Management lowered full-year guidance due to order softness and rising margin pressures, reflecting a cautious outlook for the remainder of 2025.

• These 10 stocks could mint the next wave of millionaires ›

IDEX (NYSE:IEX), a diversified engineered products manufacturer serving niche industrial and technology markets, posted its second quarter 2025 results on July 30, 2025. The company delivered adjusted earnings per share (EPS) of $2.07.—above consensus non-GAAP estimates of $1.995439. Revenue (GAAP) reached a record $865.4 million, outperforming the analyst estimate by nearly $6 million and rising 7% from the prior-year period. Despite solid execution and strong cash generation, the quarter also featured margin compression and a downward revision to full-year guidance due to softening demand in certain segments and increased macroeconomic uncertainty. Overall, the company reported a mixed quarter with notable strengths in revenue and cash flow, but with cautious signals about the back half of the year.

Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.

Understanding IDEX: Segments, Strategy, and Success Drivers

IDEX is a global provider of highly engineered industrial products and solutions. Its operations are organized into three main segments: Fluid & Metering Technologies (FMT), Health & Science Technologies (HST), and Fire & Safety/Diversified Products (FSDP). Each segment targets specialized applications in industrial, health and science, and safety markets, offering equipment such as precision pumps and fluid handling components, advanced optics, filtration systems, and fire suppression technologies.

The company’s ability to excel has relied on a blend of factors: a disciplined acquisition philosophy, targeted innovation to solve customer challenges, and operational agility through its global footprint. IDEX continues to emphasize organic growth within niche markets, strategic bolt-on acquisitions, and operational streamlining via initiatives like platform optimization and the 80/20 business principle, which focuses on prioritizing the most valuable customers and products.

Key Developments and Segment Performance in the Quarter

IDEX’s Health & Science Technologies segment was the main growth engine. HST posted GAAP net sales of $365.3 million, up 20% from the year-ago period, with 4% organic growth. Most of this expansion came from integrating Mott Corporation, acquired in September 2024, which specializes in sintered porous metal filtration products. While HST’s revenue leaped, its adjusted EBITDA margin slipped 170 basis points, reflecting the margin impact of the Mott deal and an unfavorable product mix, partly offset by productivity improvements and positive pricing actions.

The FMT segment, which includes specialized pumps, valves, and metering devices, experienced a 3% drop in GAAP net sales to $310.9 million, with organic sales down 2 %. The segment faced lower volumes in chemical, water, energy, and semiconductor end-markets. However, disciplined pricing and cost controls helped boost its adjusted EBITDA margin by 130 basis points to 35.0%, evidencing profitability improvements despite weaker demand.

Fire & Safety/Diversified Products grew net sales by 3% year over year to $191.5 million, with 2% organic sales growth. This segment benefited from North American fire original equipment manufacturer (OEM) demand and targeted growth initiatives, lifting its adjusted EBITDA margin by 40 basis points to 29.4%. However, some of these gains were offset by timing effects in projects within emerging markets, particularly in fluid dispensing.

IDEX highlighted margin pressures primarily in the HST segment, mainly from the dilutive effect of acquisitions and unfavorable mix, while FMT and FSDP segments saw margin improvement. Gross margin (GAAP) came in at 45.3%, nearly flat compared to last year, while adjusted EBITDA margin for the company as a whole edged down by 40 basis points to 27.4% (non-GAAP). Management cited acquisition-related dilution, volume deleverage, and the need for proactive cost measures—including an additional $20 million in targeted savings for FY2025—to help offset ongoing margin risks.

Cash Flow, Orders, and Other Notable Quarter Events

Free cash flow (non-GAAP) was $146.9 million, up 24.8% from $117.7 million in Q2 2024, with free cash flow conversion of 94% for the three months ended June 30, 2025. This cash generation supported continued capital deployment, including the $90.0 million purchase (plus up to $12.0 million earnout) of Micro-LAM in July 2025, which enhances capabilities in HST’s Optics Technologies family.

Order trends provided mixed signals. Orders increased 7% to $829.8 million, but the company noted some softening in rapid-turn businesses—those that handle frequent, short-cycle orders—towards the end of the quarter. Management observed cautious behaviors among customers on large projects, contributing to a less optimistic outlook for the remainder of the year. Inventories and receivables both edged higher from December 2024, reflecting the integration of new businesses.

IDEX maintained a strong balance sheet, with $568.2 million in cash as of June 30, 2025, and a modest reduction in long-term debt after repaying $100 million in senior notes.

There were no significant one-time events affecting results, aside from transaction costs and minor asset impairment charges, although GAAP results were also affected by higher amortization expense from the Mott acquisition and the absence of a gain on sale from the Alfa Valvole divestiture. No unusual activity was detected in customer order pull-forward or inventory stockpiling, with management quantifying these effects at just $6–8 million for Q1 2025.

Looking Forward: Guidance and Risks

Management provided a more cautious outlook for the remainder of FY2025. Revised full-year 2025 guidance now calls for adjusted (non-GAAP) EPS of $7.85 to $7.95, down from an earlier range of $8.10 to $8.45. The company also trimmed its full-year 2025 organic sales growth forecast to approximately 1%, citing a “reset baseline” due to order moderation and ongoing macroeconomic uncertainty. For Q3 2025, IDEX expects adjusted (non-GAAP) diluted EPS to fall between $1.90 and $1.95 on 2% to 3% organic sales growth.

Key watchpoints for the next several quarters include the trajectory of orders in short-cycle businesses, the pace and profitability of integrating recent acquisitions like Mott and Micro-LAM, and the company’s ability to mitigate ongoing margin pressures. Tariff impacts, higher employee-related costs, and uncertain demand patterns in cyclical end-markets--especially semiconductors and industrial applications--remain notable risks. Management expects proactive cost reduction measures to absorb potential volume declines of 3–4% in the back half of 2025. IDEX’s ongoing operational efficiencies, continued investment in innovation, and its focus on bolt-on acquisitions will remain important themes to monitor for investors.

Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.

Where to invest $1,000 right now

When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 1,039%* — a market-crushing outperformance compared to 182% for the S&P 500.

They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.

See the stocks »

*Stock Advisor returns as of July 29, 2025

JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.